Obesity in patients with craniopharyngioma

Endocrinologist

Volumn 16, Issue 5, 2006, Pages 286-293

  Eyal, Ori ^a,b   Sundararajan, Sumana ^c,d   Inge, Thomas H ^d   Rose, Susan R ^d,e  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

^d UNIVERSITY OF CINCINNATI   (United States)

^e CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Central obesity; Craniopharyngioma; Hypothalamic obesity; Pediatric

Indexed keywords

ANTIOBESITY AGENT; DESMOPRESSIN; DESMOPRESSIN ACETATE; DEXAMPHETAMINE; GROWTH HORMONE; HYDROCORTISONE; METFORMIN; OCTREOTIDE; SIBUTRAMINE; TESTOSTERONE; THYROXINE;

ABDOMINAL DISCOMFORT; BODY WEIGHT; CONSTIPATION; CONTROL SYSTEM; CRANIOPHARYNGIOMA; DIARRHEA; ENERGY EXPENDITURE; FOOD INTAKE; HUMAN; HYPERTENSION; HYPOTHALAMUS DISEASE; INSOMNIA; LATERAL HYPOTHALAMUS; OBESITY; POSTOPERATIVE COMPLICATION; REVIEW; RISK FACTOR; TACHYCARDIA; XEROSTOMIA; ZONA INCERTA;

EID: 33749071224     PISSN: 10512144     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ten.0000240934.07504.bc     Document Type: Review

References (16)

1. Lustig RH, Hinds PS, Ringwald-Smith K, et al. Octreotide therapy of pediatric hypothalamic obesity: a double-blind, placebo-controlled trial. J Clin Endocrinol Metab. 2003;88:2586-2592.
2. Muller HL, Emser A, Faldum A, et al. Longitudinal study on growth and body mass index before and after diagnosis of childhood craniopharyngioma. J Clin Endocrinol Metab. 2004;89:3298-3305.
3. Lustig RH, Post SR, Srivannaboon K, et al. Risk factors for the development of obesity in children surviving brain tumors. J Clin Endocrinol Metab. 2003;88:611-616.
4. Schwartz MW, Woods SC, Porte D Jr, et al. Central nervous system control of food intake. Nature. 2000;404:661-671.
5. Harz KJ, Muller HL, Waldeck E, et al. Obesity in patients with craniopharyngioma: assessment of food intake and movement counts indicating physical activity. J Clin Endocrinol Metab. 2003;88:5227-5231.
6. Gungor N, Arslanian SA. Obesity. In: Sperling, ed. Pediatric Endocrinology. Philadelphia: WB Saunders; 2002:701-716.
7. Batterham RL, Cohen MA, Ellis SM, et al. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med. 2003;349:941-948.
8. Maniatis AK, Simmons JH, Zeitler PS. Hypothalamic obesity in a patient with craniopharyngioma: dysregulation of neurohormonal control of energy balance. Curr Opin Pediatr. 2005;17:275-279.
9. Mason PW, Krawiecki N, Meacham LR. The use of dextroamphetamine to treat obesity and hyperphagia in children treated for craniopharyngioma. Arch Pediatr Adolesc Med. 2002;156:887-892.
10. Bays HE. Current and investigational antiobesity agents and obesity therapeutic treatment targets. Obes Res. 2004;12:1197-1211.
11. Korner J, Aronne LJ. Pharmacological approaches to weight reduction: therapeutic targets. J Clin Endocrinol Metab. 2004;89:2616-2621.
12. Durant N, Cox J. Current treatment approaches to overweight in adolescents. Curr Opin Pediatr. 2005;17:454-459.
13. Inge TH, Krebs NF, Garcia VF, et al. Bariatric surgery for severely overweight adolescents: concerns and recommendations. Pediatrics. 2004;114:217-223.
14. Horgan S, Holterman MJ, Jacobsen GR, et al. Laparoscopic adjustable gastric banding for the treatment of adolescent morbid obesity in the United States: a safe alternative to gastric bypass. J Pediatr Surg. 2005;40:86-90; discussion 90-91.
15. Widhalm K, Dietrich S, Prager G. Adjustable gastric banding surgery in morbidly obese adolescents: experiences with eight patients. Int J Obes Relat Metab Disord. 2004;28(suppl 3):S42-45.
16. Havel PJ. Update on adipocyte hormones: regulation of energy balance and carbohydrate/lipid metabolism. Diabetes. 2004;53(suppl 1):S143-151.